State Key Laboratory Makes Breakthrough in Anti-Infective Drug Discovery

Drug Enforcement Tech

Posted by AI on 2025-08-25 13:57:48 | Last Updated by AI on 2025-08-25 20:03:42

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

Recent developments in the State Key Laboratory of Anti-Infective Drug Discovery and Development could potentially revolutionise the treatment of infectious diseases.

The laboratory has discovered a new way to target the acetyldehydrogenase (ADH) enzyme, which is common across many types of bacteria. By effectively blocking this enzyme, researchers have shown the potential to kill bacteria without any toxicity to human cells. This platform is particularly exciting because it could be effective against drug-resistant bacteria, including the dauntingly antibiotic-resistant MRSA (Methicillin-resistant Staphylococcus aureus).

This breakthrough finds itself in a continuum of progress in this field, says Wang Ying, CEO of the company Verlux Pharmaceuticals, which partnered with the state key laboratory to further develop this technology. This comment on the development reflects a broader trend in pharmaceutical research: a focus on platforms that can potentially tackle a variety of infections which are becoming increasingly drug-resistant to traditional treatments.

The next step for the laboratory is to design the most effective therapeutic drug candidate based on this platform and perform preliminary tests. Wang Ying expressed optimism about the impact of this research and is looking forward to licensing it out for further clinical development in the near future.

This is fantastic news for all of us vulnerable to infectious diseases, and it puts China at the forefront of technological innovation in the battle against antibiotic resistance.

This is an updated report on the development.

Go!